Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention

Detection of mild cognitive impairment in a community‐dwelling population using quantitative, multiparametric MRI‐based classification

“…We also found that only those models that either used DTI-derived measures of impaired WM integrity or combined these with measures of GM atrophy were better than chance for MCI detection within the RS cohort. Nevertheless, all models resulted in similarly moderate classification performance values that were far from set criteria for acceptable detection (Bachurin et al, 2018;Thies, Truschke, Morrison-Bogorad, & Hodes, 1998). Despite previously elucidated group-wise differences (De Bruijn et al, 2014;Wang et al, 2017), it may therefore be that structural MRI-and DTI-derived measures are not sufficiently sensitive for reliable MRI-based single subject MCI detection.…”

“…Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a substantial personal and increasing societal impact (Alzheimer's Association, ; Hurd, Martorell, Delavande, Mullen, & Langa, ). Early and accurate diagnosis of AD is imperative for adequate patient management, improved personalized care, and continued development of effective disease‐modifying therapies (Alzheimer's Association, ; Bachurin, Gavrilova, Samsonova, Barreto, & Aliev, ; Petersen, ). Mild cognitive impairment (MCI) is a transitional stage where cognitive impairments are in between normal aging and very early dementia (Petersen, ).…”

“…Early and accurate diagnosis of AD is imperative for adequate patient management, improved personalized care, and continued development of effective disease-modifying therapies (Alzheimer's Association, 2018;Bachurin, Gavrilova, Samsonova, Barreto, & Aliev, 2018;Petersen, 2011). Mild cognitive impairment (MCI) is a transitional stage where cognitive impairments are in between normal aging and very early dementia (Petersen, 2016).…”

Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment

“…го научного сообщества в поиске новых терапевтических мишеней и проведении многочисленных доклинических и клинических исследований, в последние 15 лет ни один из изучавшихся препаратов не зарегистрирован в качестве средства для лечения БА. Разные противомилоидные стратегии терапии, сулившие еще в недавнем прошлом революционный прорыв в лечении этого катастрофиче-ского для пациента и его родных заболевания, так и не вышли на стадию регистрации из-за недоказанного клинического эффекта или из-за плохой переносимости «антиамилоидных» препаратов [1].…”

Mini-addenbrookes cognitive examination (M-ACE) como instrumento de avaliação cognitiva breve no comprometimento cognitivo leve e doença de Alzheimer leve

“…Nesse cenário destacam-se as pesquisas voltadas para os alvos biológicos que parecem estar envolvidos em estágios iniciais dos processos neurodegenerativos, em particular funções mitocondriais, processos de fosforilação da tau e formação de produtos oligoméricos solúveis de proteólise patológica da AРР. 35…”